Bone development

P1
How to grow a synovial joint: the cell-level activities underlying prenatal joint morphogenesis
Niamh Nowlan (Dublin, Ireland)

P2
Observational study of fetal foramen magnum and foramen magnum stenosis development in Achondroplasia
Rhoda Akilapa (London, UK)

P3
Variation in skeletal robustness is an important determinant of bone strength in youth and young adults in both males and females
Vanessa Yingling (Hayward, USA)

P4
Gene Expression Profiling of Fetal Mesenchymal Stem Cells during Osteogenic Differentiation
Emine Begüm Gencer-Öncül (Stockholm, Sweden)

P5
Variations of the trabecular bone microarchitecture through the period of locomotor behaviour development of a late 19th century post-industrial Italian population.
Antony Colombo (Pessac cedex, France)

P6
Comparison of cortical bone outcomes in the metaphysis and diaphysis during growth
Kyla Kent (Palo Alto, USA)

P7
The applicability and agreement between two methods of bone age assessment in Zimbabwean children and adolescents
Farirayi Kowo-Nyakoko (Harare, Zimbabwe)

P8
Predictors of skeletal maturity in Zimbabwean children and adolescents
Farirayi Kowo-Nyakoko (Harare, Zimbabwe)

P9
Fun with 50: testing the legend of height prediction at age two
Dana Duren (Columbia, USA)

Bone fragility

P10
Elevated Bone Turnover Markers Predict Increased Bone Mineral Density in Adolescents with Congenital Adrenal Hyperplasia
Pattara Wiromrat (Khon Kaen, Thailand)
Bone health in patients with type 1 diabetes and progressive eGFR decline from adolescence into young adulthood
Funmbi Babalola (Toronto, Canada)

Does body mass index influence the risk of vertebral fractures in children with osteogenesis imperfecta?
Sameera Auckburally (Manchester, UK)

Spontaneous Reshaping of Vertebral Fractures in Primary and Secondary Osteoporosis
Rodrigo Montero-Lopez (Linz, Austria)

Pubertal Growth in Osteogenesis Imperfecta Caused by Pathogenic Variants in COL1A1/COL1A2
Marie-Eve Robinson (Ottawa, Canada)

Burden of steroid use in the treatment of Duchenne Muscular Dystrophy: Findings from a targeted literature review, online survey and qualitative research as part of Project HERCULES
Caleb Hariri (Shotts, UK)

Histomorphometric answers to vertebral changes in sickle cell disease.
Sophia Sakka (London, UK)

Platelet-derived growth factor type BB is decreased in boys with Duchenne Muscular Dystrophy on chronic glucocorticoids without history of fracture
Julia See (Miami, USA)

SMAD3 mutation in LDS3 causes bone fragility by impairing the TGF-β pathway and enhancing osteoclastogenesis
Ahmed El-Gazzar (Linz, Austria)

Risk of chronic diseases among children with a significant fracture history
Yael Levy Shraga (Ramat Gan, Israel)

Use of Zoledronate in children with sickle cell disease: a single centre experience
Sophia Sakka (London, UK)

Use of oral risedronate in children with osteoporosis during Covid pandemic: Evelina experience
Jaya Sujatha Gopal-Kothandapani (London, UK)
Horizontal gaze palsy with progressive scoliosis secondary to ROBO3 gene variants associated with osteogenesis imperfecta type I

Belinda Crowe (London, UK)

P23
Catastrophic vertebral fracture cascade in boys with Duchenne muscular dystrophy on long-term glucocorticoids

Nicola Crabtree (Birmingham, UK)

P24
KDELR2-related Osteogenesis Imperfecta (OI21): Clinical and Radiological Features in Two Siblings with Novel Compound Heterozygous Intragenic Deletions

Catherine DeVile (London, UK)

P25
Multiple Vertebral Fractures: Was the cause hiding in plain sight: Lifestyle?

Toby Candler (Bristol, UK)

Bone Metabolism

P26
Hereditary Hypophosphatemic Rickets and Osteomalacia- An Uncommon Cause Of Metabolic Bone Disease

Shivani Shivani (Bathinda, India)

P27
The results of pharmaceutical therapy for structural disorders of bone in patients with fibrous dysplasia

Alexander Skuratov (Kyiv, Ukraine)

P28
Novel PTH gene mutations causing isolated hypoparathyroidism

Colin Hawkes (Cork, Ireland)

P29
The peculiarity of the bone metabolism in children with Wilson’s disease

Nataliya Balatska (Kyiv, Ukraine)

P30
Skeletal remodelling and resolution of recurrent severe hypercalcaemia following withdrawal of prolonged denosumab after haematopoietic stem cell transplant for TNFRSF11A osteopetrosis

Christine Burren (Bristol, UK)

P31
Osteocalcin drives metabolic adaptation in a mouse model of severe dominant Osteogenesis Imperfecta.

Josephine Tauer (Montreal, Canada)

P32
Coeliac disease presenting with vertebral fractures in a child with multiple epiphyseal dysplasia

Stephanie Borg (Sheffield, UK)
**P33**
Adiponectin has a pro-Resorption Role on Bone in Childhood-Onset Brain Tumors
**Alessio Conte** (Genoa, Italy)

**P34**
Spontaneous remission of Hypophosphataemic rickets in a child.
**Ruchi Nadar** (Birmingham, UK)

**P35**
Transient hyperphosphatasemia in a child with autism spectrum disorder
**Stepan Kutilek** (Klatovy, Czech Republic)

**P36**
Serum osteocalcin levels in children with steroid-resistant nephrotic syndrome
**Aashima Dabas** (New Delhi, India)

**Diagnostics and imaging**

**P37**
Reduced responsivity of the skull to stimuli associated with bone mineralisation at other skeletal sites in children
**Rebecca Moon** (Southampton, UK)

**P38**
Radiology reporting of paediatric osteoporotic vertebral fractures in Duchenne muscular dystrophy and potential impact on clinical management
**Hannah Martin** (Glasgow, Scotland)

**P39**
An unusual case of transient cardiac calcification identified on antenatal echocardiography – A Generalised Arterial Calcification of Infancy (GACI) like presentation.
**Jananie Suntharesan** (Liverpool, UK)

**P40**
Selective venous sampling solves the localisation dilemma in primary hyperparathyroidism.
**Nandhini Perumal** (Manchester, UK)

**P41**
Parametric analysis of a method to non-invasively quantify bone remodeling using time-lapse high-resolution peripheral quantitative computed tomography imaging from individuals with OI
**Seyedmahdi Hosseinitabatabaei** (Montreal, Canada)

**P42**
Cortical bone mass by the BoneXpert method in children and adolescents with Klinefelter syndrome.
**Jean De Schepper** (Brussels, Belgium)

**P43**
What's in a name? Prevalence of metaphyseal fractures in children with osteogenesis imperfecta in the first two years of life
Ella Riley (Sheffield, England)

P44
Osteoporosis diagnosis in adolescents by means Radiofrequency Echographic Multi Spectrometry (REMS)
Carla Caffarelli (Siena, Italy)

P45
Evidence for metaphyseal fractures typical of abuse in osteogenesis imperfecta: A Systematic Review
Ella Riley (Sheffield, England)

P46
Post-operative X-rays in Pediatric Supracondylar Fractures: What is Their Role?
Ammar Abusultan (Al Khobar, Saudi Arabia)

P47
MRI investigation of vertebral changes in children with sickle cell disease
Jaya Sujatha Gopal-Kothandapani (London, UK)

P48
Joint effusions as a radiographic feature of complex Chronic Recurrent Multifocal Osteomyelitis (CRMO)
Ioanna Tsigkouli (Stanmore, UK)

P49
A reference range for plasma levels of inorganic pyrophosphate in children
Eva Bernhard (Münster, Germany)

Genetics

P50
Dominant Osteogenesis Imperfecta Caused by a Heterozygous SP7 Variant
Karissa Ludwig (Montreal, Canada)

P51
Interrogating causal effects of epidemiological risk factors on adolescent idiopathic scoliosis (AIS): a two-sample Mendelian randomization study
Faegheh Ghanbari (Montreal, Canada)

P52
Inherited bone marrow failure syndromes: retrospective review of NGS panel testing in affected individuals
Thomas Borge (Espoo, Finland)

P53
Eiken dysplasia with Parathyroid Hormone resistance: two new paediatric cases with the same novel variant.
Alistair Calder (London, UK)

P54
Severe osteoporosis in an adolescent male with PTEN hamartoma tumour syndrome (PHTS).

**Sapna Nayak** (Manchester, UK)

**P55**
A De Novo Deleterious PHEX Variant With No Evidence Of X-Linked Hypophosphatemia

**Michelle Kayser** (New Haven, CT, USA)

**Medical therapies**

**P56**
Combination of Amiloride and Hydrochlorothiazide Improved Mineral Metabolism While Effectively Lowering Urinary Calcium Excretion in a Patient with Autosomal Dominant Hypocalcemia Type 1 Due to A Novel Gain-of-Function Mutation in the Calcium-Sensing Receptor Gene

**Matthew Benson** (Jacksonville, USA)

**P57**
Hypogonadism and low bone mineral density in adolescent males with cerebral palsy

**Alicia Diaz-Thomas** (Memphis, USA)

**P58**
Stepwise Approach to Loop Diuretic-Induced Secondary Hyperparathyroidism in Children

**Darcy Weidemann** (Kansas City, USA)

**P59**
Radiological and histomorphometric characteristic of two peripubertal X-Linked Hypophosphatemic children treated with burosumab till the end of growth

**Raja Padidela** (Manchester, UK)

**P60**
Growth pattern in children with X-linked hypophosphatemia treated with Burosumab and growth hormone

**Diana-Alexandra Ertl** (Vienna, Austria)

**P61**
Outcome of intravenous bisphosphonate greater than two years in Duchenne muscular dystrophy: A preliminary report

**Hannah Martin** (Glasgow, Scotland)

**P62**
An appraisal of a spine screening programme for vertebral fracture and its management in Duchenne Muscular Dystrophy: Is it time to reconsider threshold for treatment with bisphosphonate?

**Hannah Martin** (Glasgow, Scotland)

**P63**
Meniere’s syndrome secondary to X-linked hypophosphatemic rickets (XLHR) in an adolescent - Successfully managed with Burosumab treatment.

**Jananie Suntharesan** (Liverpool, UK)

**P64**
Dental health of pediatric patients with X-linked hypophosphatemia under one year of burosumab therapy
Avivit Brener (Tel Aviv, Israel)

P65
Resolution of tumoral calcinosis lesion and hyperostosis by Acetazolamide in Hyperphosphatemic Familial Tumoral Calcinosis and Hyperostosis Syndrome
Pon Ramya Gokul (Manchester, UK)

P66
Severity of acute phase reaction in children receiving first dose of Zoledronic acid – impact of the underlying condition
Sapna Nayak (Manchester, UK)

P67
Lipohypertrophy results in worsening of the disease state in a patient with perinatal onset hypophosphatasia treated with subcutaneous Asfotase alfa.
Lauren Rayner (Manchester, England)

P68
Boost Brittle Bones Before Birth: A Clinical Trial on Stem Cell Transplantation for Treatment of Osteogenesis Imperfecta
Oliver Semler (Cologne, Germany)

P69
Six-month safety and efficacy of asfotase alfa in a child with phosphatidylinositol glycan anchor biosynthesis class N mutation
Janet Crane (Baltimore, USA)

P70
Two years safety and efficacy outcomes of burosumab in cutaneous skeletal hypophosphatemia syndrome (CSHS)
Rachel Gafni (Bethesda, USA)

P71
Sequential therapy of PTH (1-34) with anti-IL17A prevents bone loss by amelioration of oxidative stress
Krishna Bhan Singh (Lucknow, India)

P72
Early experience of treatment of Aneurysmal Bone Cyst with a combination of Zoledronic acid and Denosumab
Benjamin Jacobs (Stanmore, UK)

P73
Growth hormone and/or testosterone prolong time to next vertebral compression fracture in dystrophinopathies managed with chronic glucocorticoids
Emely Loscalzo (Baltimore, US)

P74
Hypophosphataemic rickets secondary to McCune-Albright syndrome: successful treatment with burosumab.
Jeremy Allgrove (London, UK)

P75
Use of anti-FGF23 monoclonal antibody in the treatment of children and adolescents with X-linked hypophosphatemic rickets: argentine experience.
Hamilton Cassinelli (CABA, Argentina)

P76
A retrospective study of the biochemical and radiological profile of children with genetic hypophosphatemic rickets and their response to conventional therapy
Kebashni Thandrayen (Johannesburg, South Africa)

P77
Complications of high dose Denosumab as adjuvant therapy for recurrent pediatric giant cell tumor of the maxilla
Vivian Szymczuk (Bethesda, USA)

Mineral homeostasis and vitamin D

P78
Vitamin D supplementation during pregnancy increases offspring birth weight and calcium status: a meta-analysis of intervention studies
Harry Green (Southampton, UK)

P79
25-hydroxyvitamin D testing in paediatric secondary care: an audit of current practice
Molly Handcock (Southampton, UK)

P80
Collagen X biomarker, early childhood linear growth and bone development in a Vitamin D intervention study in Infants
Helena Hauta-alus (Helsinki, Finland)

P81
Developmental Loss of Calcium-Sensing Receptor Compensatory Response to Inflammation in Burns
Gordon Klein (Galveston, USA)

P82
Baseline vitamin D insufficiency during pubertal growth is associated with low peak bone mass in Adolescent Idiopathic Scoliosis: a 6-year prospective cohort study
Kenneth Yang (Shatin, Hong Kong)

P83
Daily versus weekly oral vitamin D3 therapy for nutritional rickets in Indian children: A randomized controlled open-label trial
Aashima Dabas (New Delhi, India)

P84
Systematic review of vitamin D supplementation in Duchenne muscular dystrophy
Jarod Wong (Glasgow, UK)
Barakat syndrome - description of two cases

**Stepan Kutilek** (Klatovy, Czech Republic)

Clinical course of hypoparathyroidism in children with autoimmune polyendocrine syndrome type-1

**Saila Laakso** (Helsinki, Finland)

Optimal 25-OH-Vitamin D level in children derived from metabolic parameters

**David Strich** (Jerusalem, Israel)

**Muscle and bone**

Anti-RANKL therapy prevents glucocorticoid induced bone loss and promotes muscle function in a mouse model of Duchenne muscular dystrophy

**Soher Jayash** (Edinburgh, UK)

A multi-disciplinary approach for bone-endocrine care in Duchenne Muscular Dystrophy: The Glasgow experience

**Jarod Wong** (Glasgow, UK)

A national survey of bone-endocrine monitoring in boys with Duchenne muscular dystrophy and the patients’ experience to inform a UK wide project to implement standards of care (DMD Care UK)

**Jarod Wong** (Glasgow, UK)

Physical impairments and activity limitations of childhood acute lymphoblastic leukemia survivors: A PETALE cohort study

**Annie Brochu** (Montreal, Canada)

Delayed puberty is very common in boys with Duchenne muscular dystrophy on daily glucocorticoid

**Jarod Wong** (Glasgow, UK)

Children with Neurofibromatosis Type 1 have significant deficits in muscle function

**Amish Chinoy** (Manchester, UK)

Whole-body vibration training in addition to muscle-strengthening exercises alone in improving muscle function in children with Neurofibromatosis Type 1 – a randomised interventional trial

**Amish Chinoy** (Manchester, UK)

Transgender youth on gonadotropin agonist have lower BMD scores but muscle strength remained similar to controls
Tandy Aye (Palo Alto, USA)

P96
Development of Musculoskeletal Deficits in Children with Cystic Fibrosis in Later Childhood
Alex Ireland (Manchester, UK)

Nutrition

P97
Comparison of infant and maternal vitamin D supplementation perspectives and practices: a cross-sectional survey study
Andrea Aul (Rochester, USA)

P98
Ultra-processed food effects on bone development and quality
Efrat Monsonego Ornan (Rehovot, Israel)

P99
Changes in biomarkers of bone turnover and incretin hormones following glucose ingestion in adolescents and young adults with pancreatic insufficient cystic fibrosis
Wang Shin Lei (Athens, USA)

P100
An audit examining the vitamin D status, prophylaxis, and treatment of vitamin D deficiency for patients in the Spinal and Scoliosis Service at Children’s Health Ireland Temple Street
Léa Sagot (Dublin, Ireland)

P101
Bone Health and diet of Guatemalan Indigenous children with impaired growth: A cross-sectional study
Michele Monroy-Valle (Saskatoon, Canada)

Orthopaedics

P102
Radiological wrist abnormalities in patients with transfusion-dependent beta-thalassemia major
Vineet Dabas (New Delhi, India)

P103
Surgical Timing and Surgeon Level in Supracondylar Humerus Fractures in Pediatric Patients: Is There an Effect on Prognosis?
Ammar Abusultan (Al Khobar, Saudi Arabia)

Other

P104
Singleton-Merten-Syndrome – from diagnosis to targeted therapy
Katrin Heldt (St Gallen, Switzerland)
P105
Duchenne muscular dystrophy: The role of eicosanoids in bone health
Malvina Hoxha (Tirana, Albania)

P106
Adolescents with Premature Ovarian Insufficiency show impaired trabecular and cortical bone density compared to Normally menstruating age and BMI matched controls
Halley Wasserman (Cincinnati, USA)

P107
Prevalence of Low Bone Density in Patients with Epidermolysis Bullosa: Insight from a Large Single Center's Experience
Halley Wasserman (Cincinnati, USA)

P108
Descriptive Study of Screening and Management of Metabolic Bone Disease of Prematurity in Neonatal Intensive-Care Unit at Montreal Children's Hospital
Laila Wazneh (Montreal, Quebec)

P109
GEnomics of MusculoSkeletal traits Translational NEtwork (GEMSTONE): Research focused on Real-World needs
Inês Alves (Évora, Portugal)

P110
Insights Into the Launch of an International Network for New Investigators in the Field of Pediatric Bone Health
Adalbert Raimann (Vienna, Austria)

P111
Development of a Dental Care Pathway for children attending a Rare Bone Disorder service at a tertiary hospital.
Eleanor Mc Govern (Dublin, Ireland)

P112
Nicola Panchbhaya (Manchester, UK)

P113
New Standards for Craniofacial Growth
Richard Sherwood (Columbia, USA)

P114
A Dual Centre Transition Clinic for Young People with Mild, Moderate and Severe Osteogenesis Imperfecta
Mark Heathfield (London, UK)

Rare bone diseases
Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Phase III Open-Label PIVOINE Rollover Trial
**Alexander Artyomenko** (Slough, UK)

P116
IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Randomized, Double-Blind, Placebo-Controlled Phase II FALKON Trial
**Fei Shih** (Cambridge, USA)

P117
First Interim Analysis of the International X-Linked Hypophosphataemia Registry: Paediatric Baseline Auxological Characteristics
**Zulf Mughal** (Manchester, UK)

P118
Lower limb maltorsion in children and adolescents with XLH
**Gabriel Mindler** (Vienna, Austria)

P119
Persistent lower limb deformities in X-linked hypophosphatemia (XLH) under Burosumab therapy: Preliminary short term results
**Gabriel Mindler** (Vienna, Austria)

P120
A systematic review of the effectiveness and safety of therapeutic options for patients with achondroplasia and clinical unmet need
**Alden Smith** (Palo Alto, USA)

P121
A systematic review on the clinical burden of achondroplasia and management of achondroplasia-associated complications
**Wahidullah Noori** (Palo Alto, USA)

P122
A novel LRRK1 mutation causing osteosclerotic metaphyseal dysplasia (OSMD)
**Chariklia Pieridou** (Coventry, UK)

P123
Gait deviations and burden of disease in children with XLH
**Alexandra Stauffer** (Vienna, Austria)

P124
The effects of systemic and local factors on regulation of skeletal and fat tissues in a mouse model of osteogenesis imperfecta
**Nitsan Nimni** (Beer Sheva, Israel)

P125
Giant Cell Tumour in lumbar spine of an 11-year-old girl – surgical and medical treatment with zoledronate and denusomab
**Signe Beck-Nielsen** (Aarhus, Denmark)

P126
Annual Hearing Screening in Children with Achondroplasia: Results from the First 2 Years in Glasgow.
**Adam Watt** (Glasgow, UK)

P127
Weak Bones Relative to Body Size in patients with Thalassemia compared to Healthy Controls
**Vanessa Yingling** (Hayward, USA)

P128
Foramen magnum stenosis in infants with achondroplasia: investigating the natural history of cervicomedullary cord compression without signal change.
**Connor Brett** (London, UK)

P129
Children with hypophosphatasia treated with asfotase alfa: interim analysis from the UK Cohort
**Raja Padidela** (Manchester, UK)

P130
Quantifying Outcomes in Fibrodysplasia Ossificans Progressiva (FOP) by Patient Age: Results from an International Burden of Illness Survey
**Kim Croskery** (Slough, UK)

P131
Circulating collagen fragments as indicators for growth in children with achondroplasia
**Merete Ljungberg** (Copenhagen, Denmark)

P132
Reduced Bone Mineral Accrual in Pediatric Patients with Thalassemia
**Ellen Fung** (Oakland, USA)

P133
Parathyroid adenoma associated with Neurofibromatosis type 1 (NF1) – A rare paediatric presentation.
**Jananie Suntharesan** (Liverpool, UK)

P134
Two heterozygous sequence variants of the CTSK gene in a girl with very small stature
**Milan Bayer** (Praha 10, Czech Republic)

P135
Identification of the CLCN7 mutation in children cause autosomal dominant osteopetrosis type II
**Voraluck Phatarakijnirund** (Bangkok, Thailand)

P136
Systematic review of muscle mass and muscle function in Osteogenesis Imperfecta
**Caleb Hariri** (Shotts, UK)

P137
Co-existence of Osteogenesis imperfecta and hypophosphatasia pathological bone features in a 3-year-old boy with multiple bone fractures and mutations in COL1A1 and ALPL.
**Nadja Fratzl-Zelman** (Vienna, Austria)
Early experience with vosoritide therapy in clinical practice
Valérie Cormier-Daire (Paris, France)

Vosoritide for Children with Achondroplasia: Growth Velocity and Pubertal Milestones
Melita Irving (London, UK)

Associations between height and health-related quality of life (HRQoL) and functional independence in children with achondroplasia
Melita Irving (London, UK)

Should Osteogenesis Imperfecta be Labeled as a Low Bone Mass Condition?
Cathleen Raggio (New York, USA)

Skeletal disease acquisition in Fibrous Dysplasia: Natural history and indicators of lesion progression in children
Vivian Szymczuk (Bethesda, Maryland, USA)

Effects of a two-week intensive training program on motor skills and mobility in children and adolescents with musculoskeletal diseases
Sandra Baumann (Linz, Austria)

Using virtual communication for rapid dissemination of COVID-19 information to individuals with osteogenesis imperfecta
Laura Tosi (Washington, DC, USA)

Craniosynostosis in Autosomal Dominant Hypophosphatemic Rickets Treated with Ferrous Sulfate
Kelli Davis (Nashville, USA)

Osteogenesis imperfecta type V in mother and child: evolution of the radiographic phenotype
Stephen Miller (Memphis, USA)

ACHieve Study: Baseline Characteristics of a Multicenter Observational Study of Children with Achondroplasia
Melita Irving (London, UK)

Baseline Characteristics of the ACcomplish Phase 2 Trial Evaluating Once-Weekly TransCon CNP in Children with Achondroplasia
Ciara McDonnell (Dublin, Ireland)

Serum phosphorus levels as a driver of skeletal morbidity in patients with fibrous dysplasia
Zubeyir Hasan Gun (Bethesda, USA)

P150
Do children aged 7-12 years old with Achondroplasia have appropriate adaptations required to support independence in toileting?
Kathryn Johnson (London, UK)

P151
Are children with achondroplasia able to use the toilet independently on entry to primary school?
Paul Watson (London, UK)

P152
Evaluation of multidisciplinary care of children with chronic metabolic bone conditions at Royal Manchester Children’s Hospital
Nicola Panchbhaya (Manchester, UK)

P153
Investigating the effect of a novel ASCC1 deletion mutation on human bone fragility
Barbara Voraberger (Linz, Austria)

P154
Functional testing of variants of uncertain significance in the ALPL gene: First results of the Hypophosphatasia gene variant consortium
Ahmed El-Gazzar (Linz, Austria)

P155
Hyperphosphatemic familial tumoral calcinosis: a case report
Yael Levy Shrag (Ramat Gan, Israel)

P156
Insights into endothelial and stromal microenvironment of osteosarcoma based on two cohorts of patients.
Valérie Trichet (Nantes, France)

P157
The Diagnostic Odyssey: Lessons from Tin Soldiers and the search for undiagnosed individuals with Fibrodysplasia Ossificans Progressiva (FOP)
Christiaan Scott (Cape Town, South Africa)

P158
The European Registries for Rare Bone and Mineral Conditions (EuRR-Bone): Focusing on the Core Registry and Disease Specific Modules
Ana Luisa Priego Zurita (Leiden, Nederland)

P159
Treatment approach for hypophosphatasia with highly purified human mesenchymal stem cells “REC”
Yasuaki Oda (Izumo-city, Japan)

P160
The global Hypophosphatasia Gene Variant Database: Dedicated to deciphering variants
Mariam Farman (Linz, Austria)
Relapse of giant cell granuloma on denosumab weaning as shown using semi-quantification of technetium Tc 99m hydroxydiphosphonate (Tc99m-HDP) uptake on SPECT imaging. 

Poonam Dharmaraj (Liverpool, Merseyside)

Engaging the osteogenesis imperfecta (OI) community in patient centered outcomes research 
Laurea Tosi (Washington, USA)

Pseudohypoparathyroidism: focus on neonatal features, a retrospective analysis of a large cohort of patients 
Giulia Del Sindaco (Milan, Italy)

Annual hearing screening in children with osteogenesis imperfecta: results from first three years in Glasgow 
Emmett Lui (Glasgow, Scotland)

Phenotypic and genotype spectrum in a cohort of patients with Osteogenesis Imperfecta. 
Nalini M Selveindran (Selangor, Malaysia)

Mechanical regulation of bone healing is altered in mouse models of osteogenesis imperfecta 
David Bertrand (Montreal, Canada)

Primary hypertrophic osteoarthropathy: a case report with genetic and rheumatology evaluation and literature review 
Marija Mijovic (Belgrade, Serbia)

Hypochondroplasia: why are we still missing its diagnosis? 
Alessandro Stefani (Genova, Italy)

What is the impact of achondroplasia on function in children as measured by the Pediatric Evaluation of Disability Inventory- Computer Adaptive Test (PEDI-CAT)? 
Jill Massey (London, UK)

Multiple Pathological Fractures as a Clinical Sign of Parathyroid Adenoma in Adolescent: a Case Report 
Frida Soesanti (Jakarta, Indonesia)

Craniofacial lesion progression in patients with fibrous dysplasia 
Kristen Pan (Bethesda, USA)
Panostotic fibrous dysplasia in newly diagnosed McCune Albright syndrome: an Indonesia experience
Frida Soesanti (Jakarta, Indonesia)

P173
Insight into the bone dysplasia mechanism of CRTAP-null osteoblasts
Aileen Barnes (Bethesda, USA)